p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. - Wikidata - awgldk - TriplyDB

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

http://www.wikidata.org/entity/Q35029530

about

Uncovering the role of p53 splice variants in human malignancy: a clinical perspective The rebel angel: mutant p53 as the driving oncogene in breast cancer.Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.Chemosensitivity and p53; new tricks by an old dog Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX p53 Isoforms: An Intracellular Microprocessor?The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer.Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.A naturally occurring 4-bp deletion in the intron 4 of p53 creates a spectrum of novel p53 isoforms with anti-apoptosis function.p53 Family: Role of Protein Isoforms in Human Cancer.Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections.Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.Prognostic significance of p53 expression in patients with esophageal cancer: a meta-analysis.Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner.The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.TP53 drives invasion through expression of its Δ133p53β variant.High-resolution functional annotation of human transcriptome: predicting isoform functions by a novel multiple instance-based label propagation method.Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.P53 and its molecular basis to chemoresistance in breast cancer.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Alternative splicing in cancer: implications for biology and therapy.New perspectives on dietary-derived treatments and food safety-antinomy in a new era.p53 Isoforms: Key Regulators of the Cell Fate Decision.Expression of p53β and Δ133p53 isoforms in different gastric tissues.Role of p53 isoforms and aggregations in cancer.Clinical Outcomes of TP53 Mutations in Cancers.Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis.The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.The p53 isoforms are differentially modified by Mdm2.The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer.Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.Identification of nonsense-mediated mRNA decay pathway as a critical regulator of p53 isoform β.Identification of p53 and its isoforms in human breast carcinoma cells.

P2860

Q27015641-83183173-9E22-4BDE-9D46-92AB46A98C1F Q27686765-58D04274-4BEB-4A18-8D51-BC29E5BD9CB8 Q28074490-E341545F-1399-4C35-A9E0-1E6826D238AE Q28079390-ADF971D4-7AF5-480C-82DF-1484FF62A6CD Q30561763-BFA597FB-524A-4FBF-87B2-AB07D4FCCB54 Q33739325-3ADB6571-0671-4F8A-8624-918D534AB4F6 Q33739357-CC19C319-0F00-4678-94FD-C2D20BA43BCC Q34202703-FA552F5E-9C4B-4BA3-91B0-C027CCD343CE Q34391735-A6D02D0B-EF5D-4AD4-8C1D-E0E481E0EB8F Q34533669-CB77657E-5029-48DC-95AE-B25DA46B3A4E Q34566248-3153CF85-6EA9-4E51-9970-B37DEFF2423F Q34586799-67850B4A-C4CC-4545-8A63-22C1B97FDAFE Q35098047-A5E2EFD8-6E05-4A49-BDDC-0957AAE59983 Q35326348-E0D2A9ED-22F6-4063-8617-44FB7E8CE894 Q35546335-4852DE95-74A0-4660-9232-B23A9B7F01B6 Q35678565-4E0E47DA-3F21-4CEC-A969-44CD7FD05232 Q35710194-845FCA1C-E70A-4F26-BFAB-85DAE369429B Q36066420-B6477C85-45A2-4C70-997C-77745B146350 Q36245341-BF227670-48E0-460D-9D86-BADDA74F2137 Q36284222-0AC891C7-AE4F-4C64-B52B-96E5E30BEE2A Q36326369-CA9B9AB0-C530-439C-AD13-78D7508BF502 Q36940496-960C7CD4-0B57-46E1-AB3E-853F913B0B12 Q37344716-923F3DC0-6B91-4BD2-B215-9B2A82F03642 Q37680589-29B086C3-0D17-42AA-8D0B-47E8449F24A0 Q37690082-441298A2-B620-4552-90D7-E95FC8FF6034 Q37982133-BF259B48-E7F3-4559-8429-8E2B4E8DA4BD Q38087850-B4AF51CF-B67F-4569-A02B-89B31A0A7BE7 Q38179828-2CA6D0E9-BD2A-460B-8280-654418584C41 Q38219163-74DC55D2-6E49-4EC4-A0CB-6D2E274D3DE6 Q38708506-6DF99E44-FCEA-485E-8FC3-725CED7BB8BB Q38815869-A49AB832-A37B-4961-BCAB-E7C227FC98BE Q38883419-239F466B-1809-40B1-B9B4-DF83A44AC571 Q38906201-E173DDA1-7FC6-4A81-978F-17FAAC268F66 Q39236844-EB2A692A-B6F4-43E4-9AFF-F1588524CAD9 Q39325284-94C964A0-4113-4953-9BA8-C74D7D1EB23C Q39367419-45EB6A7F-0E86-491F-9C9B-99C2484A7F75 Q39866578-8905D07B-98F0-4369-B30D-ADF813A9121C Q42787889-8E136ED1-B991-468B-A2D5-492B6EA85CD8 Q47131765-4CFE0E71-58F8-480A-AC31-3911367371D4 Q52647660-B7EA17D2-F87F-49ED-9A66-6290B0A2A72C

P2860

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

http://www.wikidata.org/entity/Q35029530

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

p53 mutant breast cancer patie ...... pe p53 breast cancer patients.

@ast

p53 mutant breast cancer patie ...... pe p53 breast cancer patients.

@en

type

label

p53 mutant breast cancer patie ...... pe p53 breast cancer patients.

@ast

p53 mutant breast cancer patie ...... pe p53 breast cancer patients.

@en

prefLabel

p53 mutant breast cancer patie ...... pe p53 breast cancer patients.

@ast

p53 mutant breast cancer patie ...... pe p53 breast cancer patients.

@en

P1433

Q35029530-57F5778A-2404-4C95-8CF5-CD2A2F72756D

P1476

Q35029530-1FF583FF-EF8A-4012-AFBA-2BD4E3CEDF77

P2093

Q35029530-1EBD3845-41CE-47F3-8A44-1FEA69003C46

Q35029530-3D31D928-D23D-4C7F-9317-18A87E182D41

Q35029530-7D19330F-CFA9-4016-9366-3E4028A719FE

Q35029530-991E0E64-1F7A-4299-85A3-027DFC704794

Q35029530-ACFB874C-74FD-4CEC-8859-27002E60103E

Q35029530-B7E9DA3F-DFD1-453A-99B5-2E02DE7F9B8B

Q35029530-E546F8FF-58AA-43AD-A0F4-3F6A3C99C464

P2860

Q35029530-0697D22B-F12B-4886-B1B0-65AAED3EA29A

Q35029530-074AD09F-F62B-4E07-B52B-53D689C5A88C

Q35029530-0D09DCE2-40C9-4D4D-991A-5B843530E829

Q35029530-0D5D56C4-FE77-4AEF-BB8C-E2F10BF85B9C

Q35029530-1109E09E-331A-4BA5-A94E-E1B957445234

Q35029530-16D152B4-798B-40D6-8BB7-6EBFD4AE3710

Q35029530-2E46D429-9FD4-46B5-A301-3E2AEFB87362

Q35029530-2F14B6DA-35D9-4DFA-987E-D2EBC8938686

Q35029530-58C30CD1-3801-44B0-BD25-E774A3F7AC95

Q35029530-5A802179-AB4D-4F91-8782-4417AD80DF58

P2888

Q35029530-CFCA94FE-3929-4AFF-B6FA-1723DD4DBE06

P304

Q35029530-E577192B-082D-4D22-8507-0F051897C071

P31

Q35029530-F2BA972C-96FD-494C-8690-A3BEB6A23635

P356

Q35029530-32E6458C-3B45-4D14-BCA5-2967C33E428A

P433

Q35029530-88DE1A0A-0312-40E2-BB06-D7D34BE85511

P478

Q35029530-38AF562E-69E4-4DFD-AB09-D184F6413AC5

P50

Q35029530-0A9C09FB-97FB-4E78-A788-7FC33E1573F2

Q35029530-363405D5-5BB8-4009-BEB4-87D780FF3F16

Q35029530-69089552-7370-432C-8C12-C0DCE227AE78

Q35029530-C7B9367E-EB92-40B5-A1ED-C81948085EB0

Q35029530-CA5E6EDA-3B1F-43C8-993E-38B74E71B659

P577

Q35029530-9C8FCCD2-9955-4F5E-9597-5944514D628E

P5875

Q35029530-DF385479-1FCB-48DD-852B-3E7B84771664

P6179

Q35029530-2C8D2842-FF65-4C22-A35C-B9524BE59E15

P698

Q35029530-73D4FF5B-9319-42DF-BA69-0432AF476176

P932

Q35029530-052D10A8-C139-42D2-BBB4-2169E88E5A9A

P356

P1433

Breast Cancer Research

P1476

p53 mutant breast cancer patie ...... ype p53 breast cancer patients

@en

P2093

Alastair M Thompson

http://www.w3.org/2001/XMLSchema#string

Alexandra Diot

http://www.w3.org/2001/XMLSchema#string

Kenneth Fernandes

http://www.w3.org/2001/XMLSchema#string

Lee B Jordan

http://www.w3.org/2001/XMLSchema#string

Lee Baker

http://www.w3.org/2001/XMLSchema#string

Marie P Khoury

http://www.w3.org/2001/XMLSchema#string

Mustapha Aoubala

http://www.w3.org/2001/XMLSchema#string

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

p53 isoforms can regulate p53 transcriptional activity.

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

p53 in health and disease

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence

p53 mutation, deprivation and poor prognosis in primary breast cancer

Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

P2888

P304

R7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2811

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Philip R Quinlan

Anne-Catherine Prats

Jean-Christophe Bourdon

P577

2011-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49770966

http://www.w3.org/2001/XMLSchema#string

P6179

1022254339

http://www.w3.org/2001/XMLSchema#string

P698

21251329

http://www.w3.org/2001/XMLSchema#string

P932

3109573

http://www.w3.org/2001/XMLSchema#string